At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09606 DUALITYBIO-B
Trading 11-09 13:43:06
105.000
+0.100
+0.10%
High110.000Low104.700Vol386.94K
Open105.600D1 Closing104.900Amplitude5.05%
Mkt Cap9.56BTradable Cap9.56BTotal Shares91.05M
T/O41.39MT/O Rate0.42%Tradable Shares91.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
DualityBio Executes HK$0.89 Million Buyback, Issues Options Shares; Net Outstanding Up 700 Shares
Bulletin Express  ·  11-06 19:41
DualityBio Executes HK$0.89 Million Buyback, Issues Options Shares; Net Outstanding Up 700 Shares
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.62%
HK Disclosure  ·  11-06 17:42
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.62%
Movement Alert｜DUALITYBIO-B falls 5.22% in Regular Trading, prior trial overhang outweighed buyback and chairman stake increase
Market Focus  ·  11-06
Movement Alert｜DUALITYBIO-B falls 5.22% in Regular Trading, prior trial overhang outweighed buyback and chairman stake increase
DualityBio Updates Share Capital Movements: Net Outstanding Shares Edge Down 0.01% after HKD 2.72 Million Buy-back and Option Exercises
Bulletin Express  ·  11-05
DualityBio Updates Share Capital Movements: Net Outstanding Shares Edge Down 0.01% after HKD 2.72 Million Buy-back and Option Exercises
DualityBio-B (09606) Spends Approximately HK$2.7227 Million to Repurchase 25,000 Shares on November 5
Stock News  ·  11-05
DualityBio-B (09606) Spends Approximately HK$2.7227 Million to Repurchase 25,000 Shares on November 5
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.59%
HK Disclosure  ·  11-05
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.59%
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.56%
HK Disclosure  ·  11-04
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.56%
DUALITYBIO-B (09606) Shares Rise Nearly 6% as Multiple Directors and Senior Management Make Voluntary Lock-Up Commitments; Elfe-D Expected to Become a Blockbuster Product
Stock News  ·  11-04
DUALITYBIO-B (09606) Shares Rise Nearly 6% as Multiple Directors and Senior Management Make Voluntary Lock-Up Commitments; Elfe-D Expected to Become a Blockbuster Product
Movement Alert｜DUALITYBIO-B Intraday Rise 5.03% in Regular Trading, Chair Buying and Ongoing Buybacks Support Sentiment
Market Focus  ·  11-04
Movement Alert｜DUALITYBIO-B Intraday Rise 5.03% in Regular Trading, Chair Buying and Ongoing Buybacks Support Sentiment
Insider Buying: Duality Biotherapeutics CEO & Chairman Bought CN¥3.1m Of Shares
Simply Wall St.  ·  11-04
Insider Buying: Duality Biotherapeutics CEO & Chairman Bought CN¥3.1m Of Shares
DualityBio Executes Share Buyback and Option Exercise, Trimming Net Share Count on 3 Nov 2026
Bulletin Express  ·  11-03
DualityBio Executes Share Buyback and Option Exercise, Trimming Net Share Count on 3 Nov 2026
Chairman Zhu Zhongyuan Increases Stake in DUALITYBIO-B (09606) by 30,000 Shares at HK$103.423 Each
Stock News  ·  11-03
Chairman Zhu Zhongyuan Increases Stake in DUALITYBIO-B (09606) by 30,000 Shares at HK$103.423 Each
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.53%
HK Disclosure  ·  11-03
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.53%
Movement Alert｜DUALITYBIO-B falls 5.37% in Regular Trading, clinical data concerns outweighed buyback and chairman stake increase
Market Focus  ·  11-03
Movement Alert｜DUALITYBIO-B falls 5.37% in Regular Trading, clinical data concerns outweighed buyback and chairman stake increase
Duality Biotherapeutics Executes HKD 0.99 Million Share Buyback and Issues 10.20 Thousand New Shares
Bulletin Express  ·  11-02
Duality Biotherapeutics Executes HKD 0.99 Million Share Buyback and Issues 10.20 Thousand New Shares
DUALITYBIO-B (09606) Spends HK$992,100 to Repurchase 10,000 Shares on November 2
Stock News  ·  11-02
DUALITYBIO-B (09606) Spends HK$992,100 to Repurchase 10,000 Shares on November 2
Zhu Zhongyuan Increases Stake in DUALITYBIO-B (09606) by 10,000 Shares at Approximately HK$105.72 Per Share
Stock News  ·  11-02
Zhu Zhongyuan Increases Stake in DUALITYBIO-B (09606) by 10,000 Shares at Approximately HK$105.72 Per Share
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.5%
HK Disclosure  ·  11-02
DUALITYBIO-B: 朱忠远 Acquires Shares, Long Position Rises to 17.5%
Movement Alert｜DUALITYBIO-B Falls 5.03% in Regular Trading, Clinical Data Overhang Persists Despite Insider Lock-Up
Market Focus  ·  10-30
Movement Alert｜DUALITYBIO-B Falls 5.03% in Regular Trading, Clinical Data Overhang Persists Despite Insider Lock-Up
DualityBio-B (09606) Directors and Senior Management Make Voluntary Lock-Up Commitment, Expressing Confidence in the Company's Growth Prospects
Stock News  ·  10-29
DualityBio-B (09606) Directors and Senior Management Make Voluntary Lock-Up Commitment, Expressing Confidence in the Company's Growth Prospects

Introduction

Company Name.
DUALITYBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets.
Issue price:
--